Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Chronic Lymphocytic Leukemia · Relapsing Multiple Sclerosis · TGTX

TG THERAPEUTICS

TG THERAPEUTICS, INC.

TG THERAPEUTICS clinical programs — 39 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
3020 Carrington Mill Blvd, Suite 475, Morrisville, North Carolina 27560, US HQ
2011 Founded
521 Employees
Public company Type
TGTX · NYSE Ticker
Company details
Status
Public
HQ
3020 Carrington Mill Blvd, Suite 475, Morrisville, North Carolina 27560, US
Founded
2011
Employees
521
Programs
39
Drugs
23
Patents
7
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Programs

TG THERAPEUTICS projects

39 ClinicalTrials.gov programs sponsored by TG THERAPEUTICS.

TG THERAPEUTICS has 39 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

39 programs

Clinical programs

  1. Obinutuzumab

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 3 mab terminated

    1 trial

  2. TG1101-RMS-PED304

    TG THERAPEUTICS, INC.

    Relapsing Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  3. TG1101-RMS401

    TG THERAPEUTICS, INC.

    Relapsing multiple sclerosis

    phase 3 small molecule active

    1 trial

  4. Ublituximab

    TG THERAPEUTICS, INC.

    Relapsing Multiple Sclerosis (RMS)

    phase 3 mab active

    3 trials

  5. Ublituximab

    TG THERAPEUTICS, INC.

    Diffuse Large B-Cell Lymphoma

    phase 3 mab terminated

    1 trial

  6. Ublituximab

    TG THERAPEUTICS, INC.

    Relapsing Multiple Sclerosis

    phase 3 small molecule active

    3 trials

  7. Ublituximab

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 3 small molecule completed

    5 trials

  8. Ublituximab, ublituximab

    TG THERAPEUTICS, INC.

    Relapsing forms of Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  9. ublituximab

    TG THERAPEUTICS, INC.

    relapsing multiple sclerosis

    phase 3 small molecule active

    1 trial

  10. Acalabrutinib

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  11. Pembrolizumab

    TG THERAPEUTICS, INC.

    Hodgkin's Lymphoma

    phase 2 mab terminated

    1 trial

  12. TGR-1202

    TG THERAPEUTICS, INC.

    Follicular Lymphoma

    phase 2 small molecule terminated

    1 trial

  13. TGR-1202

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 2 small molecule terminated

    1 trial

  14. Ublituximab

    TG THERAPEUTICS, INC.

    Relapsing Remitting Multiple Sclerosis

    phase 2 mab completed

    1 trial

  15. Ublituximab

    TG THERAPEUTICS, INC.

    Follicular Lymphoma

    phase 2 small molecule terminated

    1 trial

  16. Ublituximab

    TG THERAPEUTICS, INC.

    Autoimmune Disorders

    phase 2 small molecule active

    1 trial

  17. Ublituximab

    TG THERAPEUTICS, INC.

    multiple sclerosis

    phase 2 small molecule active

    1 trial

  18. Ublituximab

    TG THERAPEUTICS, INC.

    Non-Hodgkins Lymphoma

    phase 2 small molecule completed

    2 trials

  19. Umbralisib

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 2 small molecule completed

    4 trials

  20. Umbralisib

    TG THERAPEUTICS, INC.

    Lymphoma

    phase 2 small molecule terminated

    1 trial

  21. Umbralisib

    TG THERAPEUTICS, INC.

    Marginal Zone Lymphoma

    phase 2 small molecule completed

    1 trial

  22. Venetoclax

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 2 small molecule terminated

    1 trial

  23. Azercabtagene zapreleucel (azer-cel)

    TG THERAPEUTICS, INC.

    B-cell Mediated Autoimmune Disorders

    phase 1 small molecule active

    1 trial

  24. Cosibelimab

    TG THERAPEUTICS, INC.

    B-cell Non Hodgkin Lymphoma

    phase 1 small molecule terminated

    1 trial

  25. NM1F Injection

    TG THERAPEUTICS, INC.

    Ovarian Cancer

    phase 1 small molecule active

    1 trial

  26. TG-1701

    TG THERAPEUTICS, INC.

    Non Hodgkin Lymphoma

    phase 1 small molecule terminated

    1 trial

  27. TG-1801

    TG THERAPEUTICS, INC.

    B-Cell Lymphoma

    phase 1 small molecule completed

    1 trial

  28. TG-1801

    TG THERAPEUTICS, INC.

    CLL

    phase 1 mab terminated

    1 trial

  29. TG1101-RMS-SC101

    TG THERAPEUTICS, INC.

    Relapsing multiple sclerosis, Myasthenia Gravis

    phase 1 small molecule active

    1 trial

  30. TGI-5

    TG THERAPEUTICS, INC.

    CRC (Colorectal Cancer)

    phase 1 small molecule active

    1 trial

  31. TGI-6 Injection

    TG THERAPEUTICS, INC.

    Advanced or Metastatic Solid Tumors

    phase 1 small molecule active

    1 trial

  32. TGR-1202

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    phase 1 small molecule completed

    1 trial

  33. TGR-1202

    TG THERAPEUTICS, INC.

    Pancreatic Cancer

    phase 1 small molecule completed

    1 trial

  34. TGR-1202

    TG THERAPEUTICS, INC.

    Non-Hodgkin's Lymphoma

    phase 1 small molecule completed

    1 trial

  35. TGR-1202 + Obinutuzumab + Chlorambucil

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 1 small molecule completed

    1 trial

  36. TGR-1202 + brentuximab vedotin

    TG THERAPEUTICS, INC.

    Hodgkin's Lymphoma

    phase 1 small molecule completed

    1 trial

  37. Ublituximab + TGR-1202

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 1 small molecule completed

    1 trial

  38. Ublituximab

    TG THERAPEUTICS, INC.

    Multiple Sclerosis

    approved mab active

    4 trials

  39. Ublituximab

    TG THERAPEUTICS, INC.

    Multiple Sclerosis (MS) - Relapsing-remitting

    small molecule active

    1 trial

Frequently asked questions

How many clinical projects does TG THERAPEUTICS have?

39 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.